4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company's Phase I Cell Therapy Program

Summary by AI BETAClose X

4basebio PLC has partnered with TriLink BioTechnologies to supply clinical-grade opDNA® starting material for a leading pharmaceutical innovator's Phase I cell therapy program. This collaboration extends an existing relationship and leverages 4basebio's proprietary opDNA® with TriLink's GMP mRNA manufacturing capabilities and CleanCap® technology. The agreement signifies 4basebio's commitment to providing a safer, more cost-effective alternative to plasmid DNA for genetic medicine development, aiming to accelerate the path to clinical trials for the client.

Disclaimer*

Companies

4basebio (4BB)
UK 100

Latest directors dealings